Affimed N.V.

AFMD

NL0015001ZQ0

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
5.03 ^USD	+3.07%		-2.33%	-19.52%

Apr. 01	Wells Fargo Cuts Affimed Price Target to $25 From $30, Maintains Overweight Rating	MT
Apr. 01	HC Wainwright Adjusts Affimed's Price Target to $10 From $50, Maintains Buy Rating	MT

Affimed N.V. Appoints Mathieu Simon as a Supervisory Director

June 20, 2018 at 04:15 pm EDT

Affimed N.V. approved the appointment of Dr. Mathieu Simon as a supervisory director, at the AGM held on June 19, 2018.

Latest news about Affimed N.V.

Wells Fargo Cuts Affimed Price Target to $25 From $30, Maintains Overweight Rating	Apr. 01	MT
HC Wainwright Adjusts Affimed's Price Target to $10 From $50, Maintains Buy Rating	Apr. 01	MT
Affimed N.V. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28	CI
Transcript : Affimed N.V., 2023 Earnings Call, Mar 28, 2024	Mar. 28
Affimed N.V. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28	CI
Affimed N.V. Provides Clinical Response Update on AFM24-102 Trial in EGFR-Wildtype Non-Small Cell Lung Cancer	Jan. 08	CI
Affimed N.V. Announces CEO Changes	Jan. 08	CI
Affimed N.V. Announces Management Changes	Jan. 08	CI
Sector Update: Health Care Stocks Mixed Late Afternoon	Jan. 03	MT
Sector Update: Health Care Stocks Gain in Afternoon Trading	Jan. 03	MT
Affimed to Sell AbCheck to Ampersand Biomedicines for $6 Million in Cash, Stock; Shares Fall	Jan. 03	MT
Ampersand Biomedicines Inc. entered into a definitive agreement to acquire AbCheck s.r.o. from Affimed N.V. for $6.4 million.	Jan. 02	CI
Affimed N.V.(NasdaqCM:AFMD) dropped from NASDAQ Biotechnology Index	Dec. 15	CI
Transcript : Affimed N.V. - Special Call	Dec. 11
Affimed N.V. Announces Positive Data for AFM24 in Combination with the PD-L1 Checkpoint Inhibitor Atezolizumab in Heavily Pre-Treated EGFR-Wildtype Non-Small Cell Lung Cancer Patients	Dec. 11	CI
Affimed Announces Updated Phase 1/2 Data from Acimtamig in Combination with Allogeneic Nk in Hodgkin Lymphoma Patients Who Failed Prior Chemotherapy and Are Double-Refractory to Brentuximab Vedotin (Bv) and Checkpoint Inhibitors	Dec. 11	CI
Affimed Says CFO Resigns, Names Interim Successor	Nov. 30	MT
Affimed N.V. Announces Changes to its Board	Nov. 30	CI
Affimed N.V. Announces Executive Changes	Nov. 30	CI
Transcript : Affimed N.V., Q3 2023 Earnings Call, Nov 14, 2023	Nov. 14
Affimed N.V. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
Affimed N.V. Presents Preclinical Data Showing That Addition of an Innate Cell Engager to Nk and Car-Nk Cells	Nov. 03	CI
Affimed N.V. Announces Oral Presentation of Phase 1/2 Data from AFM13 in Combination with Allogeneic NK Cells at the 2023 ASH Annual Meeting	Nov. 02	CI
Affimed to Transfer Listing to Nasdaq Capital Market	23-10-04	MT
Looming Inflation Report Drags Exchange-Traded Funds, Equity Futures Lower Premarket Tuesday	23-09-12	MT

Affimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The Company's product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body's own immune system to fight tumor cells. Its pipeline includes AFM13, AFM13 + adoptive NK cells, AFM13 + anti-PD-1, AMF24, AMF26, AMF28 and AMF32. The Company is enrolling patients into a registration-directed study of AFM13 for CD30-positive relapsed/refractory peripheral T-cell Lymphoma and into a Phase 1/2a dose escalation/expansion study of AFM24 for the treatment of advanced EGFR-expressing solid tumors. Its preclinical product candidates include AMF26 for treating multiple myeloma, as well as AMF28 and AMF32, for treating of multiple tumor targets. In addition, the Company collaborates with Genentech to develop and commercialize certain product candidates for treating multiple cancers.

Sector

Biotechnology & Medical Research

Calendar

2024-05-21 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Affimed N.V.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

4.712 EUR

Average target price

20.83 EUR

Spread / Average Target

+342.11%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
AFFIMED N.V.	-19.52%	74.31M
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.71B
ARGENX SE	+1.69%	22.02B
BIONTECH SE	-17.37%	20.9B
GENMAB A/S	-9.30%	17.85B
WUXI APPTEC CO., LTD.	-41.01%	16.21B
BEIGENE, LTD.	-14.85%	15.52B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.86B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.04B

Bio Therapeutic Drugs

Affimed N.V.

Equities

AFMD

NL0015001ZQ0

Biotechnology & Medical Research

Affimed N.V. Appoints Mathieu Simon as a Supervisory Director

Latest news about Affimed N.V.

Chart Affimed N.V.

Company Profile

Income Statement Evolution

Ratings for Affimed N.V.

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs